Plesner has assisted Zealand Pharma A/S with a successful equity raise
Plesner has assisted our long-time client Zealand Pharma with an equity raise of approximately DKK 786 million through a directed issue and private placement of new ordinary shares. The equity raise qualifies as one of the largest equity raises Zealand Pharma has ever completed.
On 4 October 2022, Zealand Pharma, a company listed on Nasdaq Copenhagen, launched and completed a successful offering of new shares at a price of DKK 158 per new share, raising gross proceeds of DKK 786 million and welcoming strong new institutional investors.
Plesner is proud to have assisted our long-time client, Zealand Pharma, with the important milestone equity raise.
The proceeds enable Zealand to continue its focus on the discovery and development of innovative next generation peptide-based medicines and its goal to provide meaningful and life changing medicines to patients and families suffering from life altering metabolic and gastrointestinal diseases.
Danske Bank, Goldman Sachs International and Nordea Danmark acted as joint global coordinators and joint bookrunners. Kempen & Co. acted as co-lead manager.
Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark.